I would like to thank Dr. Per Heden, who has extensive experience of Macrolane, for
this additional information. Since March 11, 2005, the precautionary principle is
part of the French Republic constitution. The scandal PIP (Poly Implant Prothèse)
is not the first crisis that led parliamentarians to that decision. The contaminated
blood affair, mad cow diseases… have contributed to promote this basic principle a
few years ago. This communication is not only the viewpoint of Chaput et al. but also
of the AFSSAPS’ expert group who have considered that at the present time, the available
scientific literature on hyaluronic acid injections close to the breast parenchyma
was insufficient.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of Plastic, Reconstructive & Aesthetic SurgeryAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Macrolane for breast enhancement: 12-month follow-up.Plast Reconstr Surg. 2011; 127: 850-860
Compte-rendu de la Commission nationale de sécurité sanitaire des dispositifs médicaux. AFSSAPS. Séance du 3 février 2010. Point 5;pp. 8–10.
Article info
Publication history
Published online: January 19, 2012
Identification
Copyright
© 2012 Published by Elsevier Inc.
ScienceDirect
Access this article on ScienceDirectLinked Article
- Discussion: Macrolane is no longer allowed in aesthetic breast augmentation in France. Will this decision extend to the rest of the world?Journal of Plastic, Reconstructive & Aesthetic SurgeryVol. 65Issue 4
